1SMITH R E, GOOD B C. Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others[J]. Endocr Relat Cancer, 2003, 10(3):347-357.
2URSIC VRSCAJ M, KOVACIC J, BEBAR S, et al. Endometrial and other primary cancers after tamoxifen treatment of breast cancer - results of retrospective cohort study[J]. Eur J Obstet Cyneco/ Reprod Biol, 2001, 95(1): 105-110.
3DIBI R P, ZETTLER C G, PESSINI S A, et al. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer[J]. Menopause, 2009, 16(2):293-300.
4FERGUSON S E, SOSLOW R A, AMSTERDAM A, et al, Comparison of uterine malignancies that develop during and following tamoxifen ther apv[J]. Cynecol Oncol, 2006 101 (2):322-326.
5WU H, CHEN Y, SHANG Y, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen?stimulated endometrial carcinogenesis[J]. Nature, 2005,438(7070):981-987.
6AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS COMMITTEE ON GYNECOLOGIC PRACTICE. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer[J]. Obstet Cynecol, 2006,107(6):1475-1478.
7KAZEROONI T, GHAFFARPASAND F, MOSALAEI A, et al. The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxlfen[J]. Med Prine Pract, 2010, 19(3):222-227.
8GARUTI G, GROSSI F, CENTINAIO G, et al. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer[J]. Eur J Obstet Cynecol Reprod Biol, 2007, 132(1):101-106.
